2021“During the year, we made significant strides towards completing the integration of the Grupo Biotoscana acquisition, all while strengthening the team and processes and driving strong performance,” said Samira Sakhia, President and Chief Executive Officer of Knight Therapeutics in the company’s March 24 press release. “It is thanks to the hard work of our employees that we achieved unprecedented results in 2021 and we are entering 2022 with a stronger platform that is well equipped to continue delivering on further growth and success.”
-----------------------
What can we now pick up in 2022 to add to future growth?
Guessing the focus will be on finding quick bolt-on products/portfolios.